Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 476 to 500 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
476 occurrence Metaplasia (MESH:D008679) goblet cell (CL:0000160) 920: Occurrence, Metaplasia of goblet cells
477 occurrence hyperplasia (MESH:D006965) goblet cell (CL:0000160) 921: Occurrence, Hyperplasia of goblet cells
478 increased cell proliferation (GO:0008283) goblet cell (CL:0000160) 923: Increase, Proliferation of goblet cells
479 increased gene expression (GO:0010467) mucin-5AC (PR:000031343) 962: Increase, Mucin production
480 increased secretion (GO:0046903) mucin-5AC (PR:000031343) None
481 decreased respiratory function trait (VT:0002327) 1250: Decrease, Lung function
482 occurrence mucus secretion (GO:0070254) None
483 decreased biosynthetic process (GO:0009058) 5,6,7,8-tetrahydrobiopterin (CHEBI:15372) 934: KE3 : Decrease, Tetrahydrobiopterin
484 decreased proteasome complex disassembly (GO:1903009) GTP cyclohydrolase 1 (PR:000007893) 935: KE2 : Decrease, GTPCH-1
485 decreased catalytic activity (GO:0003824) nitric oxide synthase, endothelial (PR:000011328) 973: KE5 : Decrease, AKT/eNOS activity
486 decreased catalytic activity (GO:0003824) AKT kinase (PR:000029189) 973: KE5 : Decrease, AKT/eNOS activity
487 decreased nitric oxide biosynthetic process (GO:0006809) nitric oxide (CHEBI:16480) 933: KE6 : Depletion, Nitric Oxide
488 increased increased systemic vascular resistance (MP:0004878) 951: KE8 : Increase, Vascular Resistance
489 increased hypertension (MP:0000231) 952: Hypertension
490 abnormal vasodilation (GO:0042311) blood vessel (UBERON:0001981) 937: KE7 : Impaired, Vasodilation
491 abnormal antioxidant activity (GO:0016209) glutathione (CHEBI:16856) 926: Oxidation, Glutathione (To be considered with MIE)
492 increased protein glutathionylation (GO:0010731) nitric oxide synthase, endothelial (PR:000011328) 927: KE1 : S-Glutathionylation, eNOS
493 increased protein glutathionylation (GO:0010731) cysteine residue (CHEBI:32460) 927: KE1 : S-Glutathionylation, eNOS
494 functional change nitric oxide synthase, endothelial (PR:000011328) 932: KE4 : Uncoupling, eNOS
495 abnormal cardiovascular system development (GO:0072358) cardiovascular system (UBERON:0004535) 317: Altered, Cardiovascular development/function
496 increased pericardial edema (MP:0001787) 358: Increase, Pericardial edema
497 increased embryonic lethality (MP:0008762) 947: Increase, Early Life Stage Mortality
498 decreased gene expression (GO:0010467) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
499 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor (PR:000003858) 944: dimerization, AHR/ARNT
500 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor nuclear translocator (PR:000004303) 944: dimerization, AHR/ARNT